Weight gain with risperidone.

J Clin Psychopharmacol

Published: October 1997

Download full-text PDF

Source
http://dx.doi.org/10.1097/00004714-199710000-00022DOI Listing

Publication Analysis

Top Keywords

weight gain
4
gain risperidone
4
weight
1
risperidone
1

Similar Publications

In this study, data on pedigree, production traits for 19 years (2002-2022) of Salem Black goat from the Mecheri Sheep Research Station, Tamil Nadu, India was used. Various growth traits viz., birth weight (BW), weaning weight (WW), 6-month weight (6W), 9-month weight (9W), 12-month weight (YW), pre- and post-weaning average daily gain (ADG) (3-6, 6-9, 9-12 and 3-12 months) were analyzed.

View Article and Find Full Text PDF

During the harvest of Ilex paraguariensis, approximately 2-5 tons per hectare of thick stems are left on the soil surface. The outer portion of these stems, referred to as the coproduct, constitutes 30% of the total residue mass. Although this coproduct has been partially characterized in terms of its phytochemical profile, its technological applications remain unexplored.

View Article and Find Full Text PDF

Type 2 diabetes: a sacrifice program handling energy surplus.

Life Metab

December 2024

Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai 200233, China.

Type 2 diabetes mellitus (T2DM) is closely associated with obesity, while interactions between the two diseases remain to be fully elucidated. To this point, we offer this perspective to introduce a set of new insights into the interpretation of T2DM spanning the etiology, pathogenesis, and treatment approaches. These include a definition of T2DM as an energy surplus-induced diabetes characterized by the gradual decline of β cell insulin secretion function, which ultimately aims to prevent the onset of severe obesity through mechanisms of weight loss.

View Article and Find Full Text PDF

Oral Janus kinase inhibitors (JAKi) are increasingly used in dermatology, rheumatology, gastroenterology, and hematology. While effective, they can cause adverse effects such as acne, nausea, cytopenia, dyslipidemia, and Herpes zoster. Recent reports have linked JAKi usage to weight changes, particularly weight gain, which can significantly impact patients' quality of life.

View Article and Find Full Text PDF

Experiences and overall impact reported by people living with obesity: results from a multinational study.

SAGE Open Med

January 2025

Endocrinology Diabetes, Metabolism, and Obesity Medicine, Obesity, Endocrine, and Metabolism Center (OEMC), King Fahad Medical City (KFMC), Riyadh, Saudi Arabia.

Objectives: To explore the impact of obesity on clinical outcomes, health-related quality of life, emotional well-being, and work productivity in people/patients with obesity across six countries by body mass index and the presence of complications.

Methods: Adelphi Real World Obesity Disease Specific Programme™ captured data related to physicians and their consulting people/patients with obesity on a weight management program or anti-obesity medication in Brazil, Canada, China, Japan, Kingdom of Saudi Arabia, and the United Arab Emirates from April to December 2022. Physicians reported data for up to eight qualifying people/patients with obesity.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!